A 38-item questionnaire was developed to describe patient demographics and treatment characteristics. The CTSQ was developed for use in patients with any type of cancer regardless of the stage and treatments used. Each domain is scored from 0 to 100, with a higher score indicating better outcomes.

The study was an observational, cross-sectional, web-based survey of patients with breast cancer (any stage) in 2016. The study included 250 patients treated with palbociclib + AI (71.04 [12.18]) and in patients treated with palbociclib + fulvestrant (72.77 [9.20]). Patients treated with palbociclib + AI had similar CTSQ outcomes to those treated with palbociclib + fulvestrant.

Average (SD) expectations of therapy scores were 70.48 (16.11) with palbociclib + AI and 67.3 (15.15) for palbociclib + fulvestrant. Palbociclib + AI had satisfaction scores >75 (%). Patients reported satisfaction scores with palbociclib + AI (95.98 [4.41]) and fulvestrant (96.72 [2.64]) were very similar.

CONCLUSION

The majority of patients understood the benefits of palbociclib plus fulvestrant as expected.

Patients reported having high expectations of therapy with palbociclib + AI and palbociclib + fulvestrant. Satisfaction levels were similar for patients with and without visceral metastases.

The majority of patients taking palbociclib + AI and palbociclib + fulvestrant reported that side effects were in expectation, better than expected (CTSQ Item 13).

REFERENCES


